DIGITEK®

Digitek® (Digoxin Tablets), a heart medication used to treat heart failure, atrial fibrillation and atrial flutter, was manufactured by Actavis Totowa and distributed by Mylan Pharmaceuticals and UDL Laboratories, Inc. Digitek® was designed to improve the strength and efficiency of the heart, leading to better circulation of blood and reduction of the uncomfortable swelling which is common in people with congestive heart failure. On April 25, 2008, Digitek® was recalled nationwide because manufacturing problems caused some tablets to contain twice as much of the active ingredient as was appropriate. According to the FDA Medwatch Safety Alert, the recalled Digitek® was distributed by Mylan under a "Bertek" label and by UDL under a "UDL" label.

There have been several reports of severe illness and injury resulting from Digitek® use. Users with decreased kidney function, including those with renal failure or possible dehydration, may have digitalis accumulate in the body when it is not excreted normally through urine, leading to "digitalis toxicity." Digitalis toxicity can occur after one use or after chronic over medication and the outcomes can vary from arrhythmia to heart failure to death.

Symptoms of Digitalis Toxicity include:

unusual vision changes (halos, bright spots, changes in color perception, blind spots, blurred vision)
confusion or dizziness
low blood pressure
nausea, vomiting, diarrhea, loss of appetite
palpitations or irregular heartbeat
changes in urine output
swelling
difficulty breathing

If you believe that you or a loved one have been injured by taking Digitek®, please use the form below to contact our law firm and receive a free consultation.